AbbVie Inc. (ABBV) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup favors a beat — consensus is a manageable bar, Skyrizi and Rinvoq momentum has been consistently above expectations, and the July 6 IPR&D pre-disclosure has already reset the EPS baseline lower, creating a cleaner hurdle; the single biggest swing factor is whether Skyrizi IBD volumes confirm the frontline share inflection management has been signaling.

Heading into Q2 2026, AbbVie's print looks like a favorable setup. Consensus EPS of ~$3.61 (adjusted diluted) sits at the top of the July 6 guidance range of $3.57–$3.61 — a range that already absorbed a $291 million pre-tax acquired IPR&D charge from the Apogee deal, meaning the bar was effectively lowered before the quarter closed. Revenue consensus of ~$16.8B is modestly above the $16.7B Q2 guidance midpoint issued on April 29, but AbbVie has beaten its own revenue guidance in each of the last several quarters, including a $300M beat in Q1 2026. Management tone has been consistently confident: at the Goldman Sachs Healthcare Conference (June 9) and Bank of America Healthcare Conference (May 13), CFO Scott Reents explicitly stated the company is "very confident" in its 2026 numbers and sees internal Skyrizi and Rinvoq peak estimates exceeding Street consensus. Estimate revisions have been broadly stable-to-slightly-positive since the Q1 print, with the July consensus for Q2 EPS at ~$2.30 on a next-quarter basis (per revision momentum data) — though the July 6 IPR&D disclosure caused a step-down in near-term EPS estimates that has since stabilized. The stock has re-rated sharply since Q1 earnings (+26% over 3 months), with NTM P/E expanding from ~13.3x to ~17.1x, suggesting the market has already priced in continued execution; the wildcard is aesthetics — Juvederm has been a persistent drag and any incremental commentary on consumer softness or recovery could move the stock more than the immunology beat.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on both revenue and EPS given the pre-disclosed IPR&D reset; Skyrizi is the bigger swing factor — any upside to the ~$5.44B consensus estimate would confirm the IBD frontline share thesis and likely drive the stock, while aesthetics remains the key downside risk given persistent Juvederm softness.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data | Q2 2026 EPS guidance range per AbbVie 8-K filed July 6, 2026 (includes $291M pre-tax IPR&D charge from Apogee deal). Q2 2026 revenue guidance per Q1 2026 earnings call (April 29, 2026). All consensus figures as of July 30, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters — Top 2 KPIs: Total Revenue & Adj. Diluted EPS)

Source: Visible Alpha Consensus and Actuals Data. Revenue beats have been consistent across all 8 quarters; EPS misses in Q3 2025, Q4 2024, and Q4 2025 were driven by acquired IPR&D charges (non-recurring), not operational underperformance — on an ex-IPR&D basis, AbbVie has beaten adjusted EPS in 7 of the last 8 quarters.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been revised once since Q1 earnings — the July 6 8-K lowered Q2 and full-year EPS by ~$0.17 to reflect the Apogee IPR&D charge, but revenue guidance is unchanged and management tone at conferences has been consistently bullish on Skyrizi, Rinvoq, and neuroscience momentum.

Disclosure note: The July 6, 2026 8-K was the disclosure date for the revised EPS guidance. The effective date of the IPR&D charge is Q2 2026 (quarter ended June 30, 2026). The April 29, 2026 Q1 earnings call was the baseline for all initial guidance. Conference commentary at Goldman Sachs (June 9) and Bank of America (May 13) reaffirmed but did not formally revise guidance.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been broadly stable since the Q1 print, with a modest step-down in EPS following the July 6 IPR&D disclosure that has since stabilized; revenue estimates are tracking slightly above guidance midpoints, suggesting the Street is already embedding a modest beat — the gap is a cushion, not a risk.

Source: Visible Alpha Consensus and Actuals Data. The ~4% step-down in Q2 EPS estimates since the Q1 print is entirely attributable to the July 6 IPR&D disclosure and does not reflect any deterioration in operational expectations. Revenue estimates have been remarkably stable, with Skyrizi and Rinvoq consensus essentially unchanged since the Q1 print — suggesting the Street is not embedding incremental upside despite management's bullish conference commentary.

5. Stock Performance

Key Takeaway: ABBV has dramatically outperformed both XLV (+14%) and the S&P 500 (+4%) since Q1 earnings, with the +26% gain driven primarily by multiple expansion (NTM EV/EBITDA from 11.8x to 14.5x, NTM P/E from 13.3x to 17.1x) rather than estimate revisions — the re-rating reflects growing conviction in the Skyrizi/Rinvoq growth runway and the Apogee deal, but also raises the bar for the Q2 print.

Since Q1 2026 earnings (April 29, 2026), ABBV has returned approximately +26.3% (from $203.89 to $257.41 as of July 31, 2026), versus XLV at +14.5% and the S&P 500 at +4.2% over the same period. The outperformance was not linear: the stock initially dipped to ~$201 in early May before recovering, then accelerated sharply in mid-June following the Apogee acquisition announcement (June 22, +$13 on the day) and continued to grind higher through July. Key events driving the move include: (1) the Apogee deal announcement on June 22 (disclosure date), which added a late-stage IL-13 asset with quarterly/biannual dosing potential and was viewed as strategically compelling despite $10.9B price tag; (2) the July 6 8-K pre-disclosing the Q2 IPR&D charge, which paradoxically was received positively as it removed uncertainty; and (3) broad healthcare sector strength in July (XLV +9% in July alone) driven by managed care beats. The NTM P/E multiple expanded from ~13.3x to ~17.1x over the 3-month window, accounting for the majority of the price appreciation — estimate revisions contributed minimally. At current levels, ABBV trades at 17.1x NTM P/E and 14.5x NTM EV/EBITDA, both above 3-year historical averages, suggesting the stock has priced in continued execution.

Indexed Performance Table (Base = 100 at April 29, 2026 close of $203.89):

Source: Yahoo Finance / Stock Price Data. Sector ETF: XLV (Health Care Select Sector SPDR Fund) — appropriate benchmark for ABBV given its large-cap pharmaceutical classification. Indexed to 100 at April 29, 2026 close.

6. Material News & Developments (Since Q1 Earnings, April 29, 2026)

Key Takeaway: The Apogee acquisition is the most consequential post-Q1 development — it deepens the immunology pipeline with a late-stage IL-13 asset and signals AbbVie's willingness to deploy capital for near-term revenue-generating assets; the July 6 IPR&D pre-disclosure removed a key uncertainty heading into the print.

• June 22, 2026 — AbbVie Acquires Apogee Therapeutics for $10.9B (Disclosure Date: June 22, 2026; Expected Close: Q3 2026). AbbVie agreed to acquire all outstanding shares of Apogee Therapeutics at $135.11/share in cash, valuing the deal at ~$10.9B total equity value (~$10.1B net of cash). Lead asset zumilokibart (APG777) is a late-stage, half-life extended IL-13 monoclonal antibody for atopic dermatitis, with Phase 2 data showing ~two-thirds of patients achieving significant skin clearance at 16 weeks and potential for quarterly or twice-yearly maintenance dosing. APG273 (IL-13/TSLP combination) is in development for asthma. Deal is expected to be ~$0.14 dilutive to 2026 adj. EPS and ~$0.46 dilutive in 2027; accretive beginning 2032. Management sees "mega-blockbuster" (>$10B) peak sales potential. Funded with debt; AbbVie committed to 2x net leverage within 2–3 years. Implication: Deepens immunology pipeline in atopic dermatitis and asthma; adds a potential best-in-class long-acting IL-13 asset that could complement Rinvoq in AD; near-term EPS dilution is manageable given strong FCF generation.
• July 6, 2026 — AbbVie Pre-Discloses Q2 IPR&D Charge via 8-K (Disclosure Date: July 6, 2026). AbbVie filed an 8-K revising Q2 2026 adj. EPS guidance to $3.57–$3.61 (from $3.74–$3.78) and FY 2026 adj. EPS to $13.91–$14.11 (from $14.08–$14.28), reflecting a $291M pre-tax acquired IPR&D and milestones expense in Q2. Revenue guidance was unchanged. The filing explicitly noted Q2 results had not yet been finalized. Implication: Removed a key uncertainty; the EPS reset was non-operational and the market received it positively (stock rose on the day). Creates a cleaner beat/miss setup for the July 31 print.
• April 27, 2026 — Skyrizi Subcutaneous Induction Regulatory Submission in Crohn's Disease (Disclosure Date: April 27, 2026; FDA Decision Expected: H2 2026). AbbVie submitted a U.S. regulatory application for Skyrizi subcutaneous induction in Crohn's disease, supported by Phase 3 AFFIRM study data showing large efficacy deltas versus placebo in treatment-naive/frontline patients. Management expects FDA approval later in 2026. Implication: Subcu induction would remove the IV access barrier for new Crohn's patients, potentially accelerating frontline share gains and expanding the addressable market; management views this as further reinforcing Skyrizi's frontline positioning.
• May 2026 — Tavapadon (Parkinson's Disease) Approval Decision on Track for Q3 2026. Management confirmed at the Q1 earnings call (April 29) that the FDA approval decision for tavapadon in Parkinson's disease remains on track for Q3 2026. Implication: Tavapadon launch would add a third distinct Parkinson's franchise pillar to neuroscience, supporting management's $5B+ peak sales target for the Parkinson's segment.
• May 2026 — Rinvoq U.S. Regulatory Submission Completed for Alopecia Areata. AbbVie completed U.S. regulatory submissions for Rinvoq in alopecia areata; approval decisions expected in Europe and Japan later in 2026 and in the U.S. in early 2027. Implication: Adds a new indication to Rinvoq's label, expanding the addressable patient population and supporting the $10.2B FY 2026 revenue guidance.
• Q1 2026 Earnings Call (April 29, 2026) — ABBV-295 Obesity Asset Phase 1 Positive Top-Line Results. AbbVie reported positive top-line results from a multiple ascending dose study for ABBV-295 (long-acting amylin analog), showing clinically meaningful weight loss of ~10% after 12 weeks. Phase II program expected to begin in Q3 2026. Implication: Obesity pipeline is gaining credibility; management views the aesthetics channel as a natural commercial fit for obesity given overlap with injector relationships.
• Q1 2026 Earnings Call (April 29, 2026) — TrenibotE Receives FDA Complete Response Letter. FDA issued a CRL for trenibotE citing manufacturing process questions only; no safety, efficacy, or labeling concerns and no additional clinical trials requested. International approvals (Europe, Canada, Japan) remain on track for 2026. Implication: U.S. launch delayed but not derailed; international launches proceeding as planned; limited near-term revenue impact.
• Q1 2026 Earnings Call (April 29, 2026) — ABBV-932 Misses Primary Endpoint in Phase II Bipolar Depression. ABBV-932 did not achieve statistical significance in the overall Phase II bipolar depression study, though a prespecified subgroup analysis showed an efficacy signal in bipolar I patients. Next steps for bipolar I development are being evaluated. Implication: Modest pipeline setback in neuroscience; does not affect near-term revenue drivers; bipolar I subgroup signal preserves optionality.
• June 30, 2026 — National Security Probe Reported for AbbVie and Merck Over China Clinical Trials. News reports (Concentrix/stock movers coverage, June 30) referenced national security probes for Merck and AbbVie related to China clinical trials. Implication: Monitoring situation; no formal regulatory action disclosed by AbbVie; limited near-term financial impact expected but a headline risk to watch.

7. Peer Commentaries & Current-Quarter Read-Through (Last 60 Days)

Key Takeaway: Peer Q2 2026 earnings calls provide a broadly constructive read-through for ABBV — IL-23 and JAK inhibitor demand in IBD and dermatology is robust (JNJ Tremfya +71%, Caplyta +81%), the broader neuroscience market is healthy, and procedure volumes are stable; the one cautionary note is Caplyta's aggressive share gains in psychiatry, which could pressure Vraylar.

Note on methodology: Only commentary from the last 60 days (on or after May 31, 2026) that pertains to Q2 2026 current-quarter performance, forward demand, or current market dynamics is included below. Prior-quarter recap commentary (e.g., Q1 2026 results discussed on Q1 earnings calls) has been excluded. All peer earnings calls referenced below reported Q2 2026 results (quarter ended June 30, 2026).

7.1 Johnson & Johnson (JNJ) — Q2 2026 Earnings Call (July 15, 2026)

Relevance: JNJ's Tremfya (guselkumab, IL-23 inhibitor) competes directly with Skyrizi in IBD and psoriatic disease; Icodid (oral peptide IL-23) competes in psoriasis; Caplyta competes with Vraylar in psychiatry.

• Tremfya IBD demand is exceptional and confirms robust IL-23 market expansion. JNJ reported Tremfya delivered "exceptional overall sales growth of 71% in the quarter" with Q2 sales reaching $2 billion — its first $2B quarter — driven primarily by ulcerative colitis and Crohn's disease. JNJ claimed market leadership in new patient starts with 58% induction share in UC and >50% in Crohn's among IL-23 inhibitors. Read-through for ABBV: Confirms the IBD market for IL-23 inhibitors is expanding rapidly and that frontline share is the key battleground. Skyrizi's Q2 consensus of $5.44B implies ~23% YoY growth — Tremfya's 71% growth rate reflects a smaller base and earlier launch stage in IBD, but the directional signal is strongly positive for the overall IL-23 IBD market. JNJ's claim of >50% Crohn's induction share is a competitive data point to watch against Skyrizi's own frontline positioning.
• Icodid (oral IL-23) launch is market-expanding, not cannibalizing Tremfya or Skyrizi. JNJ reported >10,000 patients initiated on Icodid since launch, with 6,000 unique prescribers (>50% advanced practice providers, ~40% dermatologists) and >50% commercial coverage within 90 days. JNJ explicitly stated Icodid's launch "has not slowed down Tremfya in psoriatic disease at all" and positioned Icodid as the "first choice systemic" for patients cycling off topicals, while Tremfya is the "first choice biologic." Phase 3 studies in UC and Crohn's are "in full steam." Read-through for ABBV: Positive — confirms AbbVie's own guidance that ICOTYDE competition would have a "very modest" impact on Skyrizi. The market-expanding dynamic (oral for topical-cyclers, injectable biologic for more severe/PsA patients) supports Skyrizi's continued share leadership in the biologic segment. CFO Reents at BofA (May 13) had already guided that guidance "contemplates some share uptake by the ICO" but it is "very modest."
• Procedure volumes stable; no broad-based slowdown in demand. JNJ stated "procedure volumes continue to be stable" and "we're not seeing evidence of a broad based slowdown in demand," noting three of four MedTech businesses (surgery, vision, orthopedics) accelerated in Q2. JNJ acknowledged awareness of hospital operator reports of pressure on elective procedures but stated this is "not reflected in what we're seeing across our portfolio today." Read-through for ABBV: Indirect positive for ABBV's Botox Therapeutic (migraine, OAB) which is non-elective; limited read-through for Botox Cosmetic and Juvederm, which are more discretionary and where JNJ's portfolio is less comparable.
• Caplyta (lumateperone) growing aggressively in psychiatry — a competitive headwind for Vraylar. JNJ reported Caplyta new patient starts were "up 122% versus prior year, significantly outpacing the market leader" with 70.9% revenue growth driven by adjunctive MDD launch momentum. FDA approval for relapse prevention in schizophrenia adds a new indication. Bipolar mania data readout expected. Read-through for ABBV: Cautionary — Caplyta is gaining significant traction in the atypical antipsychotic market and is explicitly "outpacing the market leader" (likely Vraylar). This is the most direct competitive headwind in the peer read-through. Watch Vraylar new prescription trends and market share data in Q2 commentary.
• Spravato (esketamine) grew 40% YoY with 24.8% sequential growth — healthy neuroscience market. JNJ reported Spravato grew 40% year-over-year, driven by "continued strong demand from physicians and patients." Read-through for ABBV: Positive for the broader neuroscience/psychiatry market; confirms physician and patient receptivity to novel CNS treatments, which is supportive of Vraylar's continued growth and AbbVie's pipeline assets (bretisilocin, emraclidine).

7.2 Regeneron (REGN) — Q2 2026 Earnings Call (July 30, 2026)

Relevance: Regeneron's Dupixent (IL-4/IL-13 inhibitor) competes with Rinvoq in atopic dermatitis; REGN's next-generation immunology pipeline (long-acting IL-13 antibody) is a future competitor to AbbVie's Apogee acquisition (zumilokibart).

• Dupixent Q2 2026 global sales of $6B (+38% YoY constant currency) confirm robust immunology market demand. Regeneron reported Dupixent global net product sales of $6B in Q2 2026, up 38% YoY on a constant currency basis, with U.S. sales of $4.6B (+42% YoY). Growth was driven by continued penetration in atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis, plus uptake in newer indications (COPD, chronic spontaneous urticaria, bullous pemphigoid, allergic fungal sinusitis). REGN guided for H2 2026 growth to "remain strong but moderate relative to H1" as recent indication launches are annualized. Read-through for ABBV: Strongly positive for the overall immunology biologics market. Dupixent's continued 38% growth confirms that the IL-4/IL-13 and broader type 2 inflammation market remains in a robust expansion phase. Rinvoq competes in atopic dermatitis and the strong Dupixent demand suggests the overall AD market is growing, which is a rising tide for Rinvoq's AD indication.
• REGN advancing long-acting IL-13 antibody — a future competitor to Apogee's zumilokibart. Regeneron disclosed it has enrolled initial healthy subjects in a first-in-human trial for a long-acting IL-13 antibody, with atopic dermatitis patient dosing expected in Q3 2026 and registration-enabling studies potentially starting by end of 2027 or early 2028. Early clinical data indicate a "prolonged half-life" with potential for dosing intervals "well beyond those achieved with currently approved products." Read-through for ABBV: Neutral-to-cautionary for the Apogee deal thesis — REGN is developing a competing long-acting IL-13 asset, though it is at an earlier stage than zumilokibart (Phase 2 vs. first-in-human). The competitive landscape in long-acting IL-13 is becoming more crowded, which is relevant context for the $10.9B Apogee price tag.

7.3 Bristol-Myers Squibb (BMY) — Q2 2026 Earnings Call (July 30, 2026)

Relevance: BMY's Sotyktu (TYK2 inhibitor) competes in psoriasis and is expanding into lupus; Cobenfi competes with Vraylar in schizophrenia and is expanding into Alzheimer's psychosis and bipolar I.

• Sotyktu (TYK2 inhibitor) grew 23% globally in Q2 2026 — confirms robust immunology market but limited direct Skyrizi overlap. BMY reported Sotyktu global revenue grew 23% in Q2 2026, with the company supporting a recent psoriatic arthritis indication and anticipating Phase 3 readouts in lupus later this year. BMY expressed high confidence in the lupus Phase 3 data, noting they have "been able to mimic the phase two study into the phase three studies" in terms of patient demographics and endpoints. Read-through for ABBV: Broadly positive for the immunology market; Sotyktu's 23% growth confirms continued demand for novel mechanisms in psoriasis. The lupus expansion is not directly competitive with Skyrizi or Rinvoq's current indications, but the overall market health is supportive.
• Cobenfi growing 81% in schizophrenia — direct competitive pressure on Vraylar. BMY reported Cobenfi revenue grew 81% to $63M in Q2 2026, with ~15% TRX growth quarter-over-quarter and consistent increases in new prescribers. BMY noted challenges in accelerating new patient starts and improving repeat prescribing due to "deeply entrenched prescribing behavior," but sees "significant upside coming from future label expansions" including Alzheimer's psychosis (data readout beginning early 2027) and bipolar I (Phase 3 readouts in H1 2027). Read-through for ABBV: Cautionary for Vraylar — Cobenfi's 81% growth rate, while off a small base, confirms it is gaining traction in schizophrenia. Combined with Caplyta's 122% new patient start growth (JNJ), the atypical antipsychotic market is seeing meaningful competitive dynamics. Watch Vraylar's new prescription share data in Q2 commentary.
• BMY Q2 2026 beat and raised guidance — positive sector sentiment. BMY reported Q2 2026 adjusted EPS and revenue that beat analyst forecasts, driven by strong Eliquis sales (+22% to $4.48B) and newer drugs (Camzyos, Reblozyl). BMY raised full-year revenue guidance to $49–$50B (from $46–$47.5B) and adj. EPS to $6.75–$7.00 (from $6.05–$6.35). Stock rose +3.47% on the day. Read-through for ABBV: Positive sector sentiment — BMY's beat-and-raise on the same day as ABBV's earnings call creates a favorable backdrop for large-cap pharma prints.

7.4 Eli Lilly (LLY) — ADA Cardiometabolic Investor Event (June 6, 2026) & Retatrutide Announcement (July 23, 2026)

Relevance: LLY's obesity pipeline and aesthetics channel strategy are relevant to AbbVie's ABBV-295 obesity asset and aesthetics business; LLY's neuroscience expansion (AtaiBeckley acquisition for psychedelics) is relevant to AbbVie's neuroscience pipeline.

• LLY confirms obesity market is in early innings with massive unmet need — positive for ABBV-295 pipeline optionality. At the ADA Cardiometabolic Investor Event (June 6, 2026), LLY President of Cardiometabolic Health stated there are "arguably 100 million or more people living with obesity" in the U.S. and the market is in the "low single digits in terms of reaching people that we could help." Orforglipron (oral GLP-1) is seeing "strong use" in a "lower BMI population" even before full promotional activation. Read-through for ABBV: Positive for AbbVie's obesity pipeline optionality (ABBV-295 amylin analog). The massive unmet need and early-innings market penetration support AbbVie's strategic rationale for entering obesity. LLY's emphasis on the aesthetics channel overlap (injectors talking to patients about weight loss) directly validates AbbVie's stated commercial strategy.
• Retatrutide Phase 3 data shows 28–30% weight loss — raises the efficacy bar for all obesity entrants. LLY announced (July 23, 2026) it will file for FDA approval of retatrutide in Q1 2027, with Phase 3 data showing up to 28.3% weight loss at 12mg and 30.3% at the highest dose — approaching bariatric surgery-level efficacy. One-third of patients on the highest dose achieved normal BMI (<25). Read-through for ABBV: Cautionary for ABBV-295 — the efficacy bar in obesity is rising rapidly. AbbVie's amylin analog showed ~10% weight loss in Phase 1 (predominantly male, lower BMI population), which will need to demonstrate meaningfully higher efficacy in Phase 2 (higher BMI, more women) to be competitive. The differentiation thesis (tolerability, combination potential with Skyrizi in psoriasis) will be critical.
• LLY acquires AtaiBeckley for up to $3.8B (July 16, 2026) — validates psychedelic neuroscience space where ABBV has bretisilocin. LLY agreed to acquire AtaiBeckley (psychedelic drugmaker) for $6.75/share upfront ($2.8B) plus up to $2.50/share in CVRs ($1B), totaling up to $3.8B. Lead asset BPL-003 (5-MeO-DMT nasal spray) has FDA Breakthrough Therapy Designation for treatment-resistant depression and is in Phase 3. Read-through for ABBV: Positive validation for AbbVie's bretisilocin (psychoplastogen from Gilgamesh) in MDD. LLY's willingness to pay $3.8B for a Phase 3 psychedelic asset confirms the commercial and regulatory opportunity in this space. AbbVie's bretisilocin Phase 3 in MDD is planned to initiate in 2026.

7.5 AstraZeneca (AZN) — H1 2026 Results (July 27, 2026)

Relevance: AZN's oncology and rare disease performance is relevant to AbbVie's emerging oncology pipeline; AZN's ADC portfolio is a benchmark for ABBV-706 and ABBV-969.

• AZN Q2 EPS upside of $2.63 vs. $2.48 expected (+18% FXN) with full-year guidance reiterated — strength in Oncology and Rare Disease. AstraZeneca reported Q2 2026 EPS of $2.63 versus Street expectations of $2.48, with strength in Oncology and Rare Disease segments, and reiterated full-year guidance. Read-through for ABBV: Positive for the oncology market broadly; confirms that innovative oncology assets (ADCs, bispecifics) continue to see strong demand. Relevant context for AbbVie's ABBV-706 (SEZ6 ADC in SCLC) and ABBV-969 (PSMA/STEAP1 bispecific ADC in prostate cancer), which management has flagged as significantly undervalued in sell-side models.

8. Insider Transaction Activity (Since Q1 Earnings, April 29, 2026)

Key Takeaway: Insider activity since Q1 earnings is minimal and unremarkable — the only identified transaction is a single 10b5-1 planned sale by a director (Robert Alpern) of modest size; no open-market discretionary buys or unusual clustered selling patterns were identified, which is a neutral signal heading into the print.

Source: SEC Form 4 and Form 144 filings via SEC EDGAR. No open-market discretionary purchases or sales (Form 4 codes P/S) were identified for ABBV insiders in the period from April 29, 2026 through July 30, 2026. The Alpern Form 144 is a pre-planned 10b5-1 sale of shares acquired as director compensation over 2013–2017 — this is routine and carries no negative signal. The absence of any open-market buying by executives ahead of the print is neutral (not unusual given blackout periods). Overall, insider activity is unremarkable and does not provide a directional signal.

9. Catalysts & Risks

Key Takeaway: The near-term catalyst path is well-populated (Skyrizi subcu Crohn's approval, tavapadon launch, HS data, etentamig submission) and management has consistently guided to upside vs. Street consensus; the primary risks are aesthetics macro softness, Vraylar competitive pressure from Caplyta/Cobenfi, and the Apogee deal integration/dilution overhang.

Catalysts (Near-Term, H2 2026)

• Skyrizi Subcutaneous Induction Approval in Crohn's Disease (Expected H2 2026). FDA decision expected later in 2026 following April 27 regulatory submission. Approval would remove the IV access barrier for new Crohn's patients and further strengthen frontline positioning. Phase 3 AFFIRM data showed large efficacy deltas versus placebo in treatment-naive patients, exceeding management's original expectations.
• Tavapadon FDA Approval in Parkinson's Disease (Expected Q3 2026). Approval decision on track per Q1 earnings call. Launch would add a third distinct Parkinson's franchise pillar to neuroscience, supporting management's $5B+ peak sales target for the Parkinson's segment vs. Street at ~$4B.
• Rinvoq and Lutikizumab Phase 3 Top-Line Data in Hidradenitis Suppurativa (Expected H2 2026). 16-week top-line results for both Rinvoq and lutikizumab in HS expected in H2 2026. Positive data would set up a potential frontline (lutikizumab) plus second-line (Rinvoq) dynamic in HS, similar to the Skyrizi/Rinvoq IBD franchise. HS market is ~20% penetrated with advanced therapies.
• Etentamig Regulatory Submission (Expected by End of 2026, Earlier Than Prior Guidance). Regulatory submission for etentamig (BCMA-targeting bispecific) now expected by end of 2026, earlier than prior guidance. Response rate readout expected in Q3 2026 with potential interim PFS analysis. Management views etentamig as having $1B+ potential not yet reflected in most sell-side models.
• ABBV-295 Obesity Phase 1B/Phase 2 Data (Expected H2 2026 / Q3 2026 Start). Interim data from Phase 1 study in obese patients (higher BMI, more women, higher doses) expected later in 2026. Phase 2 program expected to begin in Q3 2026. Positive data would validate the obesity pipeline and support the aesthetics channel commercial strategy.
• Apogee Deal Close (Expected Q3 2026). Transaction expected to close in Q3 2026 subject to Apogee shareholder approval and regulatory approvals. Fairmount Funds and Venrock Associates have entered voting agreements in support. Close would add zumilokibart (APG777) to the commercial pipeline.
• Skyrizi + ABBV-382 Crohn's Platform Study Completion (Expected Q3 2026; Presentation Early 2027). Interim data showed endoscopic remission doubling versus either monotherapy arm at week 24 in a highly refractory population. Study expected to complete in Q3 2026 with presentation at a medical meeting by early 2027. Phase IIb starting this summer.

Risks

• Aesthetics Macro Softness (Juvederm). Juvederm global sales declined 2.9% in Q1 2026 and consensus for Q2 2026 aesthetics revenue of $1.27B implies essentially flat YoY growth. Continued consumer spending pressure on discretionary injectables could result in a miss in the aesthetics segment, which would be the most likely source of a negative surprise in Q2.
• Vraylar Competitive Pressure from Caplyta and Cobenfi. JNJ's Caplyta reported 122% new patient start growth and 70.9% revenue growth in Q2 2026, explicitly "outpacing the market leader." BMY's Cobenfi grew 81% in schizophrenia. Both are gaining traction in the atypical antipsychotic market where Vraylar holds leadership. Any deceleration in Vraylar new prescription growth would be a negative signal for the neuroscience segment.
• Apogee Deal Dilution and Integration Risk. The $10.9B Apogee acquisition is expected to be ~$0.46 dilutive to 2027 adj. EPS and accretive only beginning in 2032. Any delay in deal close, regulatory complications, or clinical setbacks for zumilokibart (APG777) in Phase 3 would weigh on the deal thesis. REGN is also advancing a competing long-acting IL-13 asset.
• Humira Biosimilar Erosion Trajectory. Humira global sales of $688M in Q1 2026 were down 40.3% YoY. Q2 2026 consensus of $732M implies a modest sequential recovery, but the ongoing biosimilar erosion trajectory remains a headwind. Any acceleration in erosion beyond consensus would be a negative surprise.
• China Clinical Trial National Security Probe. News reports (June 30, 2026) referenced a national security probe for AbbVie and Merck related to China clinical trials. No formal regulatory action has been disclosed by AbbVie. If this escalates, it could affect AbbVie's China clinical development strategy and international revenue.
• Tariff Risk on Generic Drug Manufacturing. The Trump administration has proposed 100% tariffs on generic drugs manufactured outside the U.S. (effective 2028). AbbVie's branded portfolio is less exposed than generic manufacturers, but supply chain costs and pricing dynamics could be affected. Management has not provided specific tariff guidance.
• TrenibotE U.S. Approval Delay. FDA issued a CRL for trenibotE citing manufacturing questions. Resubmission timeline is uncertain. While international launches (Europe, Canada, Japan) are proceeding, the U.S. delay limits near-term revenue contribution from this asset.